Vera Therapeutics Files 8-K Report
Ticker: VERA · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $353.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-info, filing
Related Tickers: VERA
TL;DR
VERA filed an 8-K confirming its HQ address and Nasdaq listing.
AI Summary
On October 26, 2024, Vera Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005. Vera Therapeutics' Class A common stock trades on The Nasdaq Stock Market LLC under the symbol VERA.
Why It Matters
This 8-K filing provides essential corporate information, including the company's address and stock exchange listing, which is important for investors and stakeholders to maintain accurate records.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- October 26, 2024 (date) — Date of earliest event reported
- 8000 Marina Boulevard , Suite 120 (address) — Principal executive offices
- Brisbane (location) — City of principal executive offices
- California (location) — State of principal executive offices
- 94005 (zip_code) — Zip code of principal executive offices
- VERA (ticker) — Trading Symbol
- The Nasdaq Stock Market LLC (company) — Exchange where Class A common stock is registered
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report for Vera Therapeutics, Inc., primarily confirming its principal executive office address and stock listing details.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 26, 2024.
Where are Vera Therapeutics, Inc.'s principal executive offices located?
Vera Therapeutics, Inc.'s principal executive offices are located at 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005.
On which stock exchange is Vera Therapeutics, Inc.'s Class A common stock traded?
Vera Therapeutics, Inc.'s Class A common stock is traded on The Nasdaq Stock Market LLC.
What is the trading symbol for Vera Therapeutics, Inc.'s Class A common stock?
The trading symbol for Vera Therapeutics, Inc.'s Class A common stock is VERA.
Filing Stats: 1,562 words · 6 min read · ~5 pages · Grade level 13 · Accepted 2024-10-28 17:30:56
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
- $353.2 million — f September 30, 2024 were approximately $353.2 million. The Company has not yet completed it
Filing Documents
- d891191d8k.htm (8-K) — 37KB
- d891191dex991.htm (EX-99.1) — 23KB
- d891191dex992.htm (EX-99.2) — 32KB
- g891191ex99_2p10g1.jpg (GRAPHIC) — 284KB
- g891191ex99_2p11g1.jpg (GRAPHIC) — 153KB
- g891191ex99_2p12g1.jpg (GRAPHIC) — 195KB
- g891191ex99_2p13g1.jpg (GRAPHIC) — 333KB
- g891191ex99_2p14g1.jpg (GRAPHIC) — 365KB
- g891191ex99_2p15g1.jpg (GRAPHIC) — 213KB
- g891191ex99_2p16g1.jpg (GRAPHIC) — 226KB
- g891191ex99_2p17g1.jpg (GRAPHIC) — 271KB
- g891191ex99_2p18g1.jpg (GRAPHIC) — 275KB
- g891191ex99_2p19g1.jpg (GRAPHIC) — 315KB
- g891191ex99_2p1g1.jpg (GRAPHIC) — 242KB
- g891191ex99_2p20g1.jpg (GRAPHIC) — 400KB
- g891191ex99_2p21g1.jpg (GRAPHIC) — 228KB
- g891191ex99_2p22g1.jpg (GRAPHIC) — 158KB
- g891191ex99_2p2g1.jpg (GRAPHIC) — 520KB
- g891191ex99_2p3g1.jpg (GRAPHIC) — 416KB
- g891191ex99_2p4g1.jpg (GRAPHIC) — 228KB
- g891191ex99_2p5g1.jpg (GRAPHIC) — 303KB
- g891191ex99_2p6g1.jpg (GRAPHIC) — 228KB
- g891191ex99_2p7g1.jpg (GRAPHIC) — 295KB
- g891191ex99_2p8g1.jpg (GRAPHIC) — 371KB
- g891191ex99_2p9g1.jpg (GRAPHIC) — 237KB
- g891191g1026111930546.jpg (GRAPHIC) — 27KB
- g891191g1026113001249.jpg (GRAPHIC) — 27KB
- 0001193125-24-245704.txt ( ) — 8970KB
- vera-20241026.xsd (EX-101.SCH) — 3KB
- vera-20241026_lab.xml (EX-101.LAB) — 18KB
- vera-20241026_pre.xml (EX-101.PRE) — 11KB
- d891191d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Vera Therapeutics, Inc., dated October 26, 2024. 99.2 Slide presentation entitled "Virtual Investor Event to Discuss Long-Term Results from the Phase 2b ORIGIN Study of Atacicept in IgAN Presented at ASN Kidney Week 2024". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: October 28, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer